ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Mauricio IL, Stothard JR, Miles MA, 2000. The strange case of Leishmania chagasi. Parasitol Today 16: 188–189.
-
2.
Moreno J, Alvar J, 2002. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18: 399–405.
-
3.
Berrahal F, Mary C, Roze M, Berenger A, Escoffier K, Lamouroux D, Dunan S, 1996. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am J Trop Med Hyg 55: 273–277.
-
4.
Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L, 2001. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol 39: 560–563.
-
5.
Gradoni L, Maroli M, Gramiccia M, Mancianti F, 1987. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol 1: 339–342.
-
6.
Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB, 2002. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20: 3277–3284.
-
7.
Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WD Jr, 1992. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 165: 535–540.
-
8.
Pinelli E, Killick-Kendrick R, Wagenaar J, Bernadina W, del Real G, Ruitenberg J, 1994. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62: 229–235.
-
9.
Meller-Melloul C, Farnarier C, Dunan S, Faugere B, Franck J, Mary C, Bongrand P, Quilici M, Kaplanski S, 1991. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in gamma interferon production between this population and visceral leishmaniasis patients. Parasite Immunol 13: 531–536.
-
10.
Holzmuller P, Bras-Goncalves R, Lemesre JL, 2006. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 132 (Suppl): S19–S32.
-
11.
Manson-Bahr PE, Heisch RB, Garnham PC, 1959. Studies in leishmanifasis in East Africa. IV. The Montenegro test in kala-azar in Kenya. Trans R Soc Trop Med Hyg 53: 380–383.
-
12.
Gramiccia M, Bettini S, Gradoni L, Ciarmoli P, Verrilli ML, Loddo S, Cicalo C, 1990. Leishmaniasis in Sardinia. 5. Leishmanin reaction in the human population of a focus of low endemicity of canine leishmaniasis. Trans R Soc Trop Med Hyg 84: 371–374.
-
13.
Marty P, Le Fichoux Y, Giordana D, Brugnetti A, 1992. Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France. Trans R Soc Trop Med Hyg 86: 249–250.
-
14.
Acedo Sanchez C, Martin Sanchez J, Velez Bernal ID, Sanchis Marin MC, Louassini M, Maldonado JA, Morillas Marquez F, 1996. Leishmaniasis eco-epidemiology in the Alpujarra region (Granada Province, southern Spain). Int J Parasitol 26: 303–310.
-
15.
Cardoso L, Neto F, Sousa JC, Rodrigues M, Cabral M, 1998. Use of a leishmanin skin test in the detection of canine Leishmania-specific cellular immunity. Vet Parasitol 79: 213–220.
-
16.
Solano-Gallego L, Llull J, Ramos G, Riera C, Arboix M, Alberola J, Ferrer L, 2000. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 90: 37–45.
-
17.
Dos-Santos WL, Jesus EE, Paranhos-Silva M, Pereira AM, Santos JC, Baleeiro CO, Nascimento EG, Moreira ED, Oliveira GG, Pontes-de-Carvalho LC, 2008. Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis: emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction. Vet Immunol Immunopathol 123: 251–259.
-
18.
Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, Secor WE, 2006. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69: 353–358.
-
19.
Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, Sanchez-Robert E, Francino O, Alberola J, 2007. A long term experimental study of canine visceral leishmaniasis. Int J Parasitol 37: 683–693.
-
20.
Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, Costa J, Barral-Netto M, Barral A, 2005. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
-
21.
Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, Castro T, Nogueira FS, Moreira MA, Luvizotto MC, Palatnik M, Palatnik-de-Sousa CB, 2010. Immunotherapy with the saponin enriched-Leishmune((R)) vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 28: 597–603.
-
22.
Molano I, Alonso MG, Miron C, Redondo E, Requena JM, Soto M, Nieto CG, Alonso C, 2003. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92: 1–13.
-
23.
Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA, 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23: 3716–3725.
-
24.
Khalil EA, Elhassan AM, Zijlstra EE, Osman OF, Eljack IA, Ibrahim ME, Mukhtar MM, Ghalib HW, Modabbers F, 2000. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Afr Med J 77: 468–470.
-
25.
Khalil EA, Musa AM, Modabber F, El-Hassan AM, 2006. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr 26: 357–361.
-
26.
Medin JA, Gathy K, Coleman MS, 1995. Expression of foreign proteins in Trichoplusia ni larvae. Methods Mol Biol 39: 265–275.
-
27.
Kost TA, Condreay JP, Jarvis DL, 2005. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 23: 567–575.
-
28.
Medin JA, Hunt L, Gathy K, Evans RK, Coleman MS, 1990. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc Natl Acad Sci USA 87: 2760–2764.
-
29.
Perez-Filgueira DM, Resino-Talavan P, Cubillos C, Angulo I, Barderas MG, Barcena J, Escribano JM, 2007. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 364: 422–430.
-
30.
Fragaki K, Suffia I, Ferrua B, Rousseau D, Le Fichoux Y, Kubar J, 2001. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19: 1701–1709.
-
31.
Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, Sanchez-Robert E, Francino O, Alberola J, 2007. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25: 7962–7971.
-
32.
Carson C, Antoniou M, Ruiz-Arguello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O, 2009. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 27: 1080–1086.
-
33.
Berberich C, Machado G, Morales G, Carrillo G, Jimenez-Ruiz A, Alonso C, 1998. The expression of the Leishmania infantum KMP-11 protein is developmentally regulated and stage specific. Biochim Biophys Acta 1442: 230–237.
-
34.
Todoli F, Perez-Filgueira M, Galindo I, Gomez-Sebastian S, Escribano JM, Rodriguez-Cortes A, Alberola J, 2009. Seroreactivity against raw insect-derived recombinant KMPII, TRYP, and LACK Leishmania infantum proteins in infected dogs. Vet Parasitol 164: 154–161.
-
35.
Silveira FT, Lainson R, Pereira EA, de Souza AA, Campos MB, Chagas EJ, Gomes CM, Laurenti MD, Corbett CE, 2009. A longitudinal study on the transmission dynamics of human Leishmania (Leishmania) infantum chagasi infection in Amazonian Brazil, with special reference to its prevalence and incidence. Parasitol Res 104: 559–567.
-
36.
Francino O, Altet L, Sanchez-Robert E, Rodriguez A, Solano-Gallego L, Alberola J, Ferrer L, Sanchez A, Roura X, 2006. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 137: 214–221.
-
37.
Livak KJ, Schmittgen TD, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 25: 402–408.
-
38.
Riera C, Valladares JE, Gallego M, Aisa MJ, Castillejo S, Fisa R, Ribas N, Carrio J, Alberola J, Arboix M, 1999. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84: 33–47.
-
39.
Pinheiro PH, Pinheiro AN, Ferreira JH, Costa FA, Katz S, Barbieri CL, 2009. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi as an antigen for delayed-type hypersensitivity assays and serodiagnosis of canine visceral leishmaniasis. Vet Parasitol 162: 32–39.
-
40.
Barderas MG, Wigdorovitz A, Merelo F, Beitia F, Alonso C, Borca MV, Escribano JM, 2000. Serodiagnosis of African swine fever using the recombinant protein p30 expressed in insect larvae. J Virol Methods 89: 129–136.
-
41.
Perez-Martin E, Grau-Roma L, Argilaguet JM, Nofrarias M, Escribano JM, Gomez-Sebastian S, Segales J, Rodriguez F, 2008. Development of two Trichoplusia ni larvae-derived ELISAs for the detection of antibodies against replicase and capsid proteins of porcine circovirus type 2 in domestic pigs. J Virol Methods 154: 167–174.
-
42.
Todoli F, Galindo I, Gomez-Sebastian S, Perez-Filgueira M, Escribano JM, Alberola J, Rodriguez-Cortes A, 2010. Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs. Am J Trop Med Hyg 82: 795–800.
-
43.
Riera C, Fisa R, Lopez-Chejade P, Serra T, Girona E, Jimenez M, Muncunill J, Sedeno M, Mascaro M, Udina M, Gallego M, Carrio J, Forteza A, Portus M, 2008. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 48: 1383–1389.
-
44.
Gomes RB, Brodskyn C, de Oliveira CI, Costa J, Miranda JC, Caldas A, Valenzuela JG, Barral-Netto M, Barral A, 2002. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J Infect Dis 186: 1530–1534.
-
45.
Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L, 2008. Canine leishmaniosis—new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 24: 324–330.
-
46.
Fujiwara RT, Vale AM, Franca da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Correa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A, 2005. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36: 827–838.
-
47.
Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi G Jr, 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 4103–4108.
-
48.
Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, Martinez E, Valladares B, Canavate C, Requena JM, Lopez MC, Alvar J, Moreno J, 2008. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 26: 1902–1911.
-
49.
Jensen AT, Gasim S, Ismail A, Gaafar A, Kurtzhals JA, Kemp M, El Hassan AM, Kharazmi A, Theander TG, 1998. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol 48: 103–109.
-
50.
Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A, Theander TG, 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61: 1069–1073.
-
51.
de Carvalho LP, Soto M, Jeronimo S, Dondji B, Bacellar O, Luz V, Orge Orge G, Alonso C, Jesus AR, Carvalho EM, 2003. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect 5: 7–12.
-
52.
Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, Akuffo H, 2001. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol 124: 255–261.
-
53.
Suffia I, Ferrua B, Stien X, Mograbi B, Marty P, Rousseau D, Fragaki K, Kubar J, 2000. A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun 68: 630–636.
-
54.
Carvalho LP, Passos S, Dutra WO, Soto M, Alonso C, Gollob KJ, Carvalho EM, Ribeiro de Jesus A, 2005. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. Scand J Immunol 61: 337–342.
-
55.
Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V, 2008. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26: 333–344.
-
56.
Pollock JM, McNair J, Bassett H, Cassidy JP, Costello E, Aggerbeck H, Rosenkrands I, Andersen P, 2003. Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. J Clin Microbiol 41: 1856–1860.
-
57.
Kublin JG, Lowitt MH, Hamilton RG, Oliveira GA, Nardin EH, Nussenzweig RS, Schmeckpeper BJ, Diggs CL, Bodison SA, Edelman R, 2002. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20: 1853–1861.
-
58.
Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garcon N, Leroux-Roels G, 2008. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375–1386.
-
59.
Kennedy LJ, Altet L, Angles JM, Barnes A, Carter SD, Francino O, Gerlach JA, Happ GM, Ollier WE, Polvi A, Thomson W, Wagner JL, 2000. Nomenclature for factors of the dog major histocompatibility system (DLA), 1998: first report of the ISAG DLA Nomenclature Committee. Anim Genet 31: 52–61.
-
60.
Berberich C, Requena JM, Alonso C, 1997. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp Parasitol 85: 105–108.
-
61.
Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, Reed SG, 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66: 3279–3289.
-
62.
Maalej IA, Chenik M, Louzir H, Ben Salah A, Bahloul C, Amri F, Dellagi K, 2003. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg 68: 312–320.
-
63.
Solano-Gallego L, Koutinas A, Miro G, Cardoso L, Pennisi MG, Ferrer L, Bourdeau P, Oliva G, Baneth G, 2009. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 165: 1–18.
-
64.
Rodriguez-Cortes A, Fernandez-Bellon H, Ramis A, Ferrer L, Alberola J, Solano-Gallego L, 2007. Leishmania-specific isotype levels and their relationship with specific cell-mediated immunity parameters in canine leishmaniasis. Vet Immunol Immunopathol 116: 190–198.
-
65.
Ordeix L, Solano-Gallego L, Fondevila D, Ferrer L, Fondati A, 2005. Papular dermatitis due to Leishmania spp. infection in dogs with parasite-specific cellular immune responses. Vet Dermatol 16: 187–191.
-
66.
Martinez-Moreno A, Moreno T, Martinez-Moreno FJ, Acosta I, Hernandez S, 1995. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Vet Immunol Immunopathol 48: 209–220.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 408 | 375 | 44 |
| Full Text Views | 324 | 8 | 1 |
| PDF Downloads | 85 | 6 | 1 |
Humoral and In Vivo Cellular Immunity against the Raw Insect-Derived Recombinant Leishmania infantum Antigens KMPII, TRYP, LACK, and papLe22 in Dogs from an Endemic Area
Felicitat Todolí
Felicitat Todolí
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Felicitat Todolí in
Current site
Google Scholar
PubMed
Search for other papers by Felicitat Todolí in
Current site
Google Scholar
PubMed
Laia Solano-Gallego
Laia Solano-Gallego
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Laia Solano-Gallego in
Current site
Google Scholar
PubMed
Search for other papers by Laia Solano-Gallego in
Current site
Google Scholar
PubMed
Rafael de Juan
Rafael de Juan
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Rafael de Juan in
Current site
Google Scholar
PubMed
Search for other papers by Rafael de Juan in
Current site
Google Scholar
PubMed
Pere Morell
Pere Morell
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Pere Morell in
Current site
Google Scholar
PubMed
Search for other papers by Pere Morell in
Current site
Google Scholar
PubMed
Maria del Carmen Núñez
Maria del Carmen Núñez
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Maria del Carmen Núñez in
Current site
Google Scholar
PubMed
Search for other papers by Maria del Carmen Núñez in
Current site
Google Scholar
PubMed
Rodrigo Lasa
Rodrigo Lasa
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Rodrigo Lasa in
Current site
Google Scholar
PubMed
Search for other papers by Rodrigo Lasa in
Current site
Google Scholar
PubMed
Silvia Gómez-Sebastián
Silvia Gómez-Sebastián
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Silvia Gómez-Sebastián in
Current site
Google Scholar
PubMed
Search for other papers by Silvia Gómez-Sebastián in
Current site
Google Scholar
PubMed
José M. Escribano
José M. Escribano
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by José M. Escribano in
Current site
Google Scholar
PubMed
Search for other papers by José M. Escribano in
Current site
Google Scholar
PubMed
Jordi Alberola
Jordi Alberola
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Jordi Alberola in
Current site
Google Scholar
PubMed
Search for other papers by Jordi Alberola in
Current site
Google Scholar
PubMed
Alhelí Rodríguez-Cortés
Alhelí Rodríguez-Cortés
Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom; Centre Sanitari Municipal de Protecció Animal, Palma (Mallorca), Spain; Alternative Gene Expression (ALGENEX) S.L., Madrid, Spain; Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria (INIA), Madrid, Spain
Search for other papers by Alhelí Rodríguez-Cortés in
Current site
Google Scholar
PubMed
Search for other papers by Alhelí Rodríguez-Cortés in
Current site
Google Scholar
PubMed
Leishmania infantum causes visceral leishmaniasis, a severe zoonotic and systemic disease that is fatal if left untreated. Identification of the antigens involved in Leishmania-specific protective immune response is a research priority for the development of effective control measures. For this purpose, we evaluated, in 27 dogs from an enzootic zone, specific humoral and cellular immune response by delayed-type hypersensitivity (DTH) skin test both against total L. infantum antigen and the raw Trichoplusia ni insect-derived kinetoplastid membrane protein-11 (rKMPII), tryparedoxin peroxidase (rTRYP), Leishmania homologue of receptors for activated C kinase (rLACK), and 22-kDa potentially aggravating protein of Leishmania (rpapLe22) antigens from this parasite. rTRYP induced the highest number of positive DTH responses (55% of leishmanin skin test [LST]-positive dogs), showing that TRYP antigen is an important T cell immunogen, and it could be a promising vaccine candidate against this disease. When TRYP-DTH and KMPII-DTH tests were evaluated in parallel, 82% of LST-positive dogs were detected, suggesting that both antigens could be considered as components of a standardized DTH immunodiagnostic tool for dogs.
Author Notes
Financial support: F.T. was supported by Generalitat de Catalunya Grant 2005 FI 01116. This work was financed by Projects BIO2004-03893 and AGL2008-00748 (both for J.A.) from the Spanish Government.
Authors' addresses: Felicitat Todolí, Jordi Alberola, and Alhelí Rodríguez-Cortés, Unitat de Farmacologia Veterinària and LeishLAB–Servei d'Anàlisi de Fàrmacs, Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain, E-mails: Felicitat.Todoli@uab.cat, Jordi.Alberola@uab.cat, and Alheli.Rodriguez@uab.cat. Laia Solano-Gallego, Department of Pathology and Infectious Diseases, Royal Veterinary College, University of London, Hertfordshire, United Kingdom, E-mail: lsolano@rvc.ac.uk. Rafael de Juan and Pere Morell, Centre Sanitari Municipal de Protecció Animal, Palma, Mallorca, Spain, E-mails: rdjuan@sf.a-palma.es and centreproteccioanimal@sf.a-palma.es. Maria del Carmen Núñez, Rodrigo Lasa, and Silvia Gómez-Sebastián, Alternative Gene Expression S.L. (ALGENEX), Centro Empresarial, Parque Científico y Tecnológico de la Universidad Politécnica de Madrid, Campus de Montegancedo, Madrid, Spain, E-mails: mcn@algenex.es, rlc@algenex.es, and sgs@algenex.es. José M. Escribano, Departamento de Biotecnología, Instituto Nacional de Investigación y Tecnologia Agraria y Alimentaria, Madrid, Spain, E-mail: escriban@inia.es.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Mauricio IL, Stothard JR, Miles MA, 2000. The strange case of Leishmania chagasi. Parasitol Today 16: 188–189.
-
2.
Moreno J, Alvar J, 2002. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol 18: 399–405.
-
3.
Berrahal F, Mary C, Roze M, Berenger A, Escoffier K, Lamouroux D, Dunan S, 1996. Canine leishmaniasis: identification of asymptomatic carriers by polymerase chain reaction and immunoblotting. Am J Trop Med Hyg 55: 273–277.
-
4.
Solano-Gallego L, Morell P, Arboix M, Alberola J, Ferrer L, 2001. Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology. J Clin Microbiol 39: 560–563.
-
5.
Gradoni L, Maroli M, Gramiccia M, Mancianti F, 1987. Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment. Med Vet Entomol 1: 339–342.
-
6.
Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Souza E, Santos WR, Gomes EM, Luz KG, Palatnik M, Palatnik de Sousa CB, 2002. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (Sao Goncalo do Amarante, RN). Vaccine 20: 3277–3284.
-
7.
Carvalho EM, Barral A, Pedral-Sampaio D, Barral-Netto M, Badaro R, Rocha H, Johnson WD Jr, 1992. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 165: 535–540.
-
8.
Pinelli E, Killick-Kendrick R, Wagenaar J, Bernadina W, del Real G, Ruitenberg J, 1994. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum. Infect Immun 62: 229–235.
-
9.
Meller-Melloul C, Farnarier C, Dunan S, Faugere B, Franck J, Mary C, Bongrand P, Quilici M, Kaplanski S, 1991. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in gamma interferon production between this population and visceral leishmaniasis patients. Parasite Immunol 13: 531–536.
-
10.
Holzmuller P, Bras-Goncalves R, Lemesre JL, 2006. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxide-mediated programmed cell death in Leishmania. Parasitology 132 (Suppl): S19–S32.
-
11.
Manson-Bahr PE, Heisch RB, Garnham PC, 1959. Studies in leishmanifasis in East Africa. IV. The Montenegro test in kala-azar in Kenya. Trans R Soc Trop Med Hyg 53: 380–383.
-
12.
Gramiccia M, Bettini S, Gradoni L, Ciarmoli P, Verrilli ML, Loddo S, Cicalo C, 1990. Leishmaniasis in Sardinia. 5. Leishmanin reaction in the human population of a focus of low endemicity of canine leishmaniasis. Trans R Soc Trop Med Hyg 84: 371–374.
-
13.
Marty P, Le Fichoux Y, Giordana D, Brugnetti A, 1992. Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France. Trans R Soc Trop Med Hyg 86: 249–250.
-
14.
Acedo Sanchez C, Martin Sanchez J, Velez Bernal ID, Sanchis Marin MC, Louassini M, Maldonado JA, Morillas Marquez F, 1996. Leishmaniasis eco-epidemiology in the Alpujarra region (Granada Province, southern Spain). Int J Parasitol 26: 303–310.
-
15.
Cardoso L, Neto F, Sousa JC, Rodrigues M, Cabral M, 1998. Use of a leishmanin skin test in the detection of canine Leishmania-specific cellular immunity. Vet Parasitol 79: 213–220.
-
16.
Solano-Gallego L, Llull J, Ramos G, Riera C, Arboix M, Alberola J, Ferrer L, 2000. The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection. Vet Parasitol 90: 37–45.
-
17.
Dos-Santos WL, Jesus EE, Paranhos-Silva M, Pereira AM, Santos JC, Baleeiro CO, Nascimento EG, Moreira ED, Oliveira GG, Pontes-de-Carvalho LC, 2008. Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis: emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction. Vet Immunol Immunopathol 123: 251–259.
-
18.
Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C, Secor WE, 2006. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 69: 353–358.
-
19.
Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, Sanchez-Robert E, Francino O, Alberola J, 2007. A long term experimental study of canine visceral leishmaniasis. Int J Parasitol 37: 683–693.
-
20.
Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, Costa J, Barral-Netto M, Barral A, 2005. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113.
-
21.
Borja-Cabrera GP, Santos FN, Santos FB, Trivellato FA, Kawasaki JK, Costa AC, Castro T, Nogueira FS, Moreira MA, Luvizotto MC, Palatnik M, Palatnik-de-Sousa CB, 2010. Immunotherapy with the saponin enriched-Leishmune((R)) vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis. Vaccine 28: 597–603.
-
22.
Molano I, Alonso MG, Miron C, Redondo E, Requena JM, Soto M, Nieto CG, Alonso C, 2003. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol 92: 1–13.
-
23.
Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, Sanos S, Kaye P, Taghikhani M, Jamshidi S, Rad MA, 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23: 3716–3725.
-
24.
Khalil EA, Elhassan AM, Zijlstra EE, Osman OF, Eljack IA, Ibrahim ME, Mukhtar MM, Ghalib HW, Modabbers F, 2000. Safety and immunogenicity of an autoclaved Leishmania major vaccine. East Afr Med J 77: 468–470.
-
25.
Khalil EA, Musa AM, Modabber F, El-Hassan AM, 2006. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study. Ann Trop Paediatr 26: 357–361.
-
26.
Medin JA, Gathy K, Coleman MS, 1995. Expression of foreign proteins in Trichoplusia ni larvae. Methods Mol Biol 39: 265–275.
-
27.
Kost TA, Condreay JP, Jarvis DL, 2005. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 23: 567–575.
-
28.
Medin JA, Hunt L, Gathy K, Evans RK, Coleman MS, 1990. Efficient, low-cost protein factories: expression of human adenosine deaminase in baculovirus-infected insect larvae. Proc Natl Acad Sci USA 87: 2760–2764.
-
29.
Perez-Filgueira DM, Resino-Talavan P, Cubillos C, Angulo I, Barderas MG, Barcena J, Escribano JM, 2007. Development of a low-cost, insect larvae-derived recombinant subunit vaccine against RHDV. Virology 364: 422–430.
-
30.
Fragaki K, Suffia I, Ferrua B, Rousseau D, Le Fichoux Y, Kubar J, 2001. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine 19: 1701–1709.
-
31.
Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L, Timon M, Altet L, Solano-Gallego L, Sanchez-Robert E, Francino O, Alberola J, 2007. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25: 7962–7971.
-
32.
Carson C, Antoniou M, Ruiz-Arguello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O, 2009. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 27: 1080–1086.
-
33.
Berberich C, Machado G, Morales G, Carrillo G, Jimenez-Ruiz A, Alonso C, 1998. The expression of the Leishmania infantum KMP-11 protein is developmentally regulated and stage specific. Biochim Biophys Acta 1442: 230–237.
-
34.
Todoli F, Perez-Filgueira M, Galindo I, Gomez-Sebastian S, Escribano JM, Rodriguez-Cortes A, Alberola J, 2009. Seroreactivity against raw insect-derived recombinant KMPII, TRYP, and LACK Leishmania infantum proteins in infected dogs. Vet Parasitol 164: 154–161.
-
35.
Silveira FT, Lainson R, Pereira EA, de Souza AA, Campos MB, Chagas EJ, Gomes CM, Laurenti MD, Corbett CE, 2009. A longitudinal study on the transmission dynamics of human Leishmania (Leishmania) infantum chagasi infection in Amazonian Brazil, with special reference to its prevalence and incidence. Parasitol Res 104: 559–567.
-
36.
Francino O, Altet L, Sanchez-Robert E, Rodriguez A, Solano-Gallego L, Alberola J, Ferrer L, Sanchez A, Roura X, 2006. Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis. Vet Parasitol 137: 214–221.
-
37.
Livak KJ, Schmittgen TD, 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 25: 402–408.
-
38.
Riera C, Valladares JE, Gallego M, Aisa MJ, Castillejo S, Fisa R, Ribas N, Carrio J, Alberola J, Arboix M, 1999. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate. Vet Parasitol 84: 33–47.
-
39.
Pinheiro PH, Pinheiro AN, Ferreira JH, Costa FA, Katz S, Barbieri CL, 2009. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi as an antigen for delayed-type hypersensitivity assays and serodiagnosis of canine visceral leishmaniasis. Vet Parasitol 162: 32–39.
-
40.
Barderas MG, Wigdorovitz A, Merelo F, Beitia F, Alonso C, Borca MV, Escribano JM, 2000. Serodiagnosis of African swine fever using the recombinant protein p30 expressed in insect larvae. J Virol Methods 89: 129–136.
-
41.
Perez-Martin E, Grau-Roma L, Argilaguet JM, Nofrarias M, Escribano JM, Gomez-Sebastian S, Segales J, Rodriguez F, 2008. Development of two Trichoplusia ni larvae-derived ELISAs for the detection of antibodies against replicase and capsid proteins of porcine circovirus type 2 in domestic pigs. J Virol Methods 154: 167–174.
-
42.
Todoli F, Galindo I, Gomez-Sebastian S, Perez-Filgueira M, Escribano JM, Alberola J, Rodriguez-Cortes A, 2010. Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs. Am J Trop Med Hyg 82: 795–800.
-
43.
Riera C, Fisa R, Lopez-Chejade P, Serra T, Girona E, Jimenez M, Muncunill J, Sedeno M, Mascaro M, Udina M, Gallego M, Carrio J, Forteza A, Portus M, 2008. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 48: 1383–1389.
-
44.
Gomes RB, Brodskyn C, de Oliveira CI, Costa J, Miranda JC, Caldas A, Valenzuela JG, Barral-Netto M, Barral A, 2002. Seroconversion against Lutzomyia longipalpis saliva concurrent with the development of anti-Leishmania chagasi delayed-type hypersensitivity. J Infect Dis 186: 1530–1534.
-
45.
Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L, 2008. Canine leishmaniosis—new concepts and insights on an expanding zoonosis: part one. Trends Parasitol 24: 324–330.
-
46.
Fujiwara RT, Vale AM, Franca da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Correa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A, 2005. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 36: 827–838.
-
47.
Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, Reed SG, Grimaldi G Jr, 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69: 4103–4108.
-
48.
Carrillo E, Crusat M, Nieto J, Chicharro C, Thomas Mdel C, Martinez E, Valladares B, Canavate C, Requena JM, Lopez MC, Alvar J, Moreno J, 2008. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine 26: 1902–1911.
-
49.
Jensen AT, Gasim S, Ismail A, Gaafar A, Kurtzhals JA, Kemp M, El Hassan AM, Kharazmi A, Theander TG, 1998. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand J Immunol 48: 103–109.
-
50.
Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A, Theander TG, 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 61: 1069–1073.
-
51.
de Carvalho LP, Soto M, Jeronimo S, Dondji B, Bacellar O, Luz V, Orge Orge G, Alonso C, Jesus AR, Carvalho EM, 2003. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect 5: 7–12.
-
52.
Maasho K, Wolday D, Edjigu M, Soderstrom K, Britton S, Akuffo H, 2001. Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis. Clin Exp Immunol 124: 255–261.
-
53.
Suffia I, Ferrua B, Stien X, Mograbi B, Marty P, Rousseau D, Fragaki K, Kubar J, 2000. A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. Infect Immun 68: 630–636.
-
54.
Carvalho LP, Passos S, Dutra WO, Soto M, Alonso C, Gollob KJ, Carvalho EM, Ribeiro de Jesus A, 2005. Effect of LACK and KMP11 on IFN-gamma production by peripheral blood mononuclear cells from cutaneous and mucosal leishmaniasis patients. Scand J Immunol 61: 337–342.
-
55.
Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, Larraga V, 2008. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26: 333–344.
-
56.
Pollock JM, McNair J, Bassett H, Cassidy JP, Costello E, Aggerbeck H, Rosenkrands I, Andersen P, 2003. Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. J Clin Microbiol 41: 1856–1860.
-
57.
Kublin JG, Lowitt MH, Hamilton RG, Oliveira GA, Nardin EH, Nussenzweig RS, Schmeckpeper BJ, Diggs CL, Bodison SA, Edelman R, 2002. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20: 1853–1861.
-
58.
Vandepapeliere P, Horsmans Y, Moris P, Van Mechelen M, Janssens M, Koutsoukos M, Van Belle P, Clement F, Hanon E, Wettendorff M, Garcon N, Leroux-Roels G, 2008. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26: 1375–1386.
-
59.
Kennedy LJ, Altet L, Angles JM, Barnes A, Carter SD, Francino O, Gerlach JA, Happ GM, Ollier WE, Polvi A, Thomson W, Wagner JL, 2000. Nomenclature for factors of the dog major histocompatibility system (DLA), 1998: first report of the ISAG DLA Nomenclature Committee. Anim Genet 31: 52–61.
-
60.
Berberich C, Requena JM, Alonso C, 1997. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp Parasitol 85: 105–108.
-
61.
Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, Reed SG, 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66: 3279–3289.
-
62.
Maalej IA, Chenik M, Louzir H, Ben Salah A, Bahloul C, Amri F, Dellagi K, 2003. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am J Trop Med Hyg 68: 312–320.
-
63.
Solano-Gallego L, Koutinas A, Miro G, Cardoso L, Pennisi MG, Ferrer L, Bourdeau P, Oliva G, Baneth G, 2009. Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis. Vet Parasitol 165: 1–18.
-
64.
Rodriguez-Cortes A, Fernandez-Bellon H, Ramis A, Ferrer L, Alberola J, Solano-Gallego L, 2007. Leishmania-specific isotype levels and their relationship with specific cell-mediated immunity parameters in canine leishmaniasis. Vet Immunol Immunopathol 116: 190–198.
-
65.
Ordeix L, Solano-Gallego L, Fondevila D, Ferrer L, Fondati A, 2005. Papular dermatitis due to Leishmania spp. infection in dogs with parasite-specific cellular immune responses. Vet Dermatol 16: 187–191.
-
66.
Martinez-Moreno A, Moreno T, Martinez-Moreno FJ, Acosta I, Hernandez S, 1995. Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis. Vet Immunol Immunopathol 48: 209–220.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 408 | 375 | 44 |
| Full Text Views | 324 | 8 | 1 |
| PDF Downloads | 85 | 6 | 1 |